Selective Inhibition of NaV1.8 with VX-548 for Acute Pain.
Jim Jones, Darin J Correll, Sandra M Lechner...
https://pubmed.ncbi.nlm.nih.gov/37530822/Actively Recruiting
Led by University of California, San Diego · Updated on 2026-07-06
100
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are evaluating the effectiveness of suzetrigine for managing acute postoperative pain in surgical patients who are identified as high risk for persistent postoperative opioid use POU. This study uses a validated artificial intelligence model called SurgNet-POU to analyze electronic health records and predict the risk of POU, defined as needing opioids for 3 months or more after surgery. The trial focuses on adults undergoing major orthopedic, breast, gynecological, or abdominal surgeries who are at higher risk for long-term opioid use. Participants will be randomly assigned to one of two groups standard care alone, which includes usual outpatient opioid and other analgesic prescriptions by their surgical team, or standard care combined with a 14-day course of suzetrigine. Those in the suzetrigine group will take 100 mg orally about 1 to 2 hours before surgery, then 50 mg twice daily for 14 days after surgery. No placebo will be given to the standard care group. This approach aims to assess suzetrigines potential to reduce opioid consumption and pain following surgery. Throughout the study, participants opioid use will be tracked for 14 days as the primary outcome, with additional monitoring of opioid use and pain scores at 7, 14, 30, and 90 days after surgery. Researchers will also assess opioid-related side effects during these time points. The total study period includes enrollment before surgery and follow-up assessments up to three months postoperatively to evaluate pain levels and persistent opioid use risks.
CONDITIONS
Precision Pain Management - A Randomized Clinical Trial Assessing the Efficacy of Suzetrigine on Postoperative Analgesia Among Surgical Patients at Higher Risk for Persistent Postoperative Opioid Use (POU)
R
Rodney A Gabriel
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of California, San Diego
Lead Sponsor
Wellcome Leap Inc.
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Suzetrigine + Standard Care | Standard Care Alone |
|---|---|---|
| What it is | An investigational non‑opioid NaV1.8 inhibitor (suzetrigine) taken for 14 days in addition to standard postoperative analgesia | Standard postoperative analgesia as routinely prescribed by the surgical team |
| Primary use | Studied for reducing postoperative opioid consumption among patients at high risk for persistent opioid use | Used as the trial control reflecting current postoperative analgesia practice |
| Evidence status | Effectiveness for postoperative opioid reduction is under investigation in this randomized study | Represents current usual care practice supported by multimodal analgesia guidelines |
| Important risks | Safety profile of suzetrigine is not yet established in this surgical population | Risks inherent to standard postoperative analgesia depend on agent choices and are managed per surgical protocols |
| Important limitations | No published efficacy or safety results yet; applicability limited to high‑risk surgical patients | Definition of ‘standard care’ may vary across surgical teams and institutions affecting consistency |
| Patient impact | Not yet known, pending trial results | Supports established recovery practices aimed at managing pain and minimizing opioid use |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person or virtual) for screening and consent
Duration - 14 days
Participants receive either standard outpatient pain care alone or standard care combined with suzetrigine. Those in the suzetrigine group take a dose before surgery and then twice daily for 14 days after surgery.
Regular follow-up visits or calls during the 14-day treatment period
Duration - Up to 3 months
Participants are monitored for pain levels, opioid use, and side effects at 7, 14, 30, and 90 days after surgery.
Scheduled visits or assessments at 7, 14, 30, and 90 days post-surgery
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Jim Jones, Darin J Correll, Sandra M Lechner...
https://pubmed.ncbi.nlm.nih.gov/37530822/Todd Bertoch, Dominick D'Aunno, Jessica McCoun...
https://pubmed.ncbi.nlm.nih.gov/40117446/Jessica McCoun, Peter Winkle, Daneshvari Solanki...
https://pubmed.ncbi.nlm.nih.gov/40165940/University of California, San Diego
Lead Sponsor
Wellcome Leap Inc.
Collaborating Sponsor